Osteoporosis, Postmenopausal Clinical Trial
Official title:
Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates
The aim of this study is see the changes in bone mineral density after discontinuation or stop the use of bisphosphonates and make the switch to bazedoxifene).
The primary hypothesis is: "Comparing to control group (Calcium+VitD), Bazedoxifene group
(20mg daily+ calcium+VitD) is efficient in reducing BMD in spine at 12 months of treatment.
in postmenopausal women switching from daily, weekly or monthly bisphosphonates therapy. It
is a non-inferiority study of Bazedoxifene compared to biphosphonates, being each patient
its own control from the baseline. It is a superiority study of Bazedoxifene compared to
Calcium+VitD.
Taking into account the difference in the percentage change observed in the total BMD of the
spine during 12 months in those patients treated with Bazedoxifene+Ca+VitD at least 110
patients should be included, 55 in each arm of treatment.
This simple size is going to allow us to detect the differences in the percentage change
observed in the total BMD of the spine during 12 months between the two treatment arms,
being the same or over 0.25%, with a significance level of 95%, an 80% power. It is
estimated a standard deviation of 0.5%, and a 10% lost follow-up rate.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03931109 -
Circulating miRNA in Primary Hyperparathyroidism
|
||
Not yet recruiting |
NCT03232476 -
Effect of Mechanical Loading With PTH on Cortical Bone
|
Phase 4 | |
Completed |
NCT02884401 -
Peri-implant Bone Changes in Post-menopausal Osteoporotic Women
|
N/A | |
Completed |
NCT00073190 -
Patient- and Physician-Based Osteoporosis Education
|
Phase 1 | |
Completed |
NCT00402441 -
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
|
Phase 4 | |
Completed |
NCT03710889 -
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
|
Phase 3 | |
Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
Recruiting |
NCT05058976 -
Romosozumab Use to Build Skeletal Integrity
|
Phase 4 | |
Active, not recruiting |
NCT05405894 -
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
|
||
Recruiting |
NCT03337971 -
Nutritional Supplement and Bone Health in Post-Menopausal Women
|
N/A | |
Completed |
NCT03701113 -
Milk Protein and Bone Health in Postmenopausal Women
|
N/A | |
Completed |
NCT01381588 -
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
|
N/A | |
Completed |
NCT00383422 -
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
|
Phase 3 | |
Completed |
NCT00549965 -
Satisfaction and Compliance of Risedronate in PMO
|
Phase 4 | |
Completed |
NCT00035256 -
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
|
Phase 4 | |
Completed |
NCT01386281 -
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
|
||
Completed |
NCT05266261 -
Use of Ibandronate in Diabetic Patients
|
N/A | |
Recruiting |
NCT04964388 -
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
|
Phase 2 | |
Active, not recruiting |
NCT03623633 -
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
|
Phase 4 | |
Recruiting |
NCT05575167 -
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
|